CATX has 36-month beta value of 1.46. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CATX is 48.31M, and currently, short sellers hold a 14.39% ratio of that float. The average trading volume of CATX on September 11, 2024 was 886.89K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CATX) stock’s latest price update
Perspective Therapeutics Inc (AMEX: CATX) has experienced a decline in its stock price by -2.53 compared to its previous closing price of 15.82. However, the company has seen a gain of 2.94% in its stock price over the last five trading days. globenewswire.com reported 2024-09-05 that SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma.
CATX’s Market Performance
CATX’s stock has risen by 2.94% in the past week, with a monthly rise of 27.54% and a quarterly rise of 22.38%. The volatility ratio for the week is 6.18% while the volatility levels for the last 30 days are 7.36% for Perspective Therapeutics Inc The simple moving average for the past 20 days is 3.65% for CATX’s stock, with a 41.99% simple moving average for the past 200 days.
Analysts’ Opinion of CATX
Many brokerage firms have already submitted their reports for CATX stocks, with BofA Securities repeating the rating for CATX by listing it as a “Buy.” The predicted price for CATX in the upcoming period, according to BofA Securities is $24 based on the research report published on July 25, 2024 of the current year 2024.
CATX Trading at 16.25% from the 50-Day Moving Average
After a stumble in the market that brought CATX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.06% of loss for the given period.
Volatility was left at 7.36%, however, over the last 30 days, the volatility rate increased by 6.18%, as shares surge +20.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.05% upper at present.
During the last 5 trading sessions, CATX rose by +2.47%, which changed the moving average for the period of 200-days by +501.96% in comparison to the 20-day moving average, which settled at $15.01. In addition, Perspective Therapeutics Inc saw 283.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CATX starting from Hunt Jonathan Robert, who purchase 1,800 shares at the price of $9.81 back on Jun 17 ’24. After this action, Hunt Jonathan Robert now owns 35,971 shares of Perspective Therapeutics Inc, valued at $17,667 using the latest closing price.
Woods Lori A, the Director of Perspective Therapeutics Inc, purchase 4,587 shares at $10.90 during a trade that took place back on Jun 14 ’24, which means that Woods Lori A is holding 159,985 shares at $49,990 based on the most recent closing price.
Stock Fundamentals for CATX
Current profitability levels for the company are sitting at:
- -6.32 for the present operating margin
- 0.07 for the gross margin
The net margin for Perspective Therapeutics Inc stands at -4.17. The total capital return value is set at -0.32. Equity return is now at value -29.53, with -27.07 for asset returns.
Based on Perspective Therapeutics Inc (CATX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -8.44. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -551.88.
Currently, EBITDA for the company is -14.84 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 195.79. The receivables turnover for the company is 3.03for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 27.73.
Conclusion
To put it simply, Perspective Therapeutics Inc (CATX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
